Stock Analysis on Net
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Pfizer Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019
Short-term borrowings, including current portion of long-term debt 4.42 5.52 3.72 4.57 1.19 1.81 2.14 1.49 2.07 3.07 0.35 1.23 2.03 2.29 2.74 1.75 7.47 7.35 9.62 9.67 9.75 6.73 6.05
Trade accounts payable 2.42 2.36 2.53 2.96 2.48 2.76 3.13 3.45 3.21 3.18 2.99 3.07 2.62 2.55 2.56 2.79 2.31 2.18 2.39 2.52 2.31 2.56 2.67
Dividends payable 0.00 1.10 0.00 1.05 0.00 1.05 0.00 1.17 1.15 1.15 0.00 1.24 1.22 1.29 0.00 1.40 1.18 1.19 0.00 1.26 1.17 1.27 0.00
Income taxes payable 1.31 1.33 1.44 1.04 0.88 1.33 1.01 0.80 1.57 1.72 1.73 0.70 2.51 1.03 0.88 0.68 0.80 0.81 0.69 0.59 1.11 0.98 1.19
Accrued compensation and related items 1.54 1.19 0.99 1.23 1.10 0.90 1.16 1.73 1.46 1.02 1.22 1.84 1.43 1.19 1.25 1.98 1.35 1.15 1.35 1.62 1.39 1.20 1.16
Deferred revenues 0.92 1.17 1.13 1.19 1.03 0.58 0.89 1.28 3.17 1.95 1.69 1.69 1.97 2.53 1.29 0.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other current liabilities 9.08 7.59 8.50 9.07 7.80 7.30 10.35 11.44 10.06 12.20 13.37 13.74 11.55 10.13 8.06 7.47 5.97 5.72 6.32 6.62 5.96 7.76 7.86
Current liabilities 19.69% 20.27% 18.32% 21.10% 14.48% 15.74% 18.69% 21.37% 22.68% 24.28% 21.36% 23.51% 23.33% 20.99% 16.78% 16.81% 19.08% 18.39% 20.37% 22.27% 21.69% 20.51% 18.93%
Long-term debt, excluding current portion 26.43 26.60 27.73 27.17 28.39 27.87 16.21 16.68 16.70 17.56 19.40 19.94 20.23 20.81 22.26 24.08 27.82 28.40 21.81 21.47 21.15 23.16 22.99
Pension and postretirement benefit obligations 0.94 0.94 0.94 0.96 1.01 0.99 1.11 1.14 1.52 1.67 1.90 2.05 2.40 2.91 3.25 3.51 3.60 3.61 3.93 4.04 3.77 4.03 4.15
Noncurrent deferred tax liabilities 0.98 1.03 0.42 0.28 0.52 0.56 0.55 0.52 0.32 0.29 0.36 0.19 0.18 2.45 2.74 2.63 2.54 3.04 3.17 3.33 3.94 2.04 2.31
Other taxes payable 2.69 3.02 3.89 3.77 3.77 3.66 5.04 4.98 4.97 5.63 6.30 6.24 6.33 6.63 7.40 7.50 6.55 6.45 7.34 7.24 7.34 7.95 9.47
Other noncurrent liabilities 7.09 7.44 6.84 7.30 6.62 6.09 6.65 6.68 6.27 5.79 5.72 5.37 5.13 4.84 4.21 4.32 3.83 3.83 4.10 3.77 3.74 3.96 4.08
Noncurrent liabilities 38.14% 39.04% 39.82% 39.48% 40.31% 39.16% 29.56% 29.99% 29.76% 30.93% 33.66% 33.80% 34.28% 37.63% 39.86% 42.04% 44.32% 45.32% 40.34% 39.85% 39.94% 41.13% 43.01%
Total liabilities 57.83% 59.31% 58.14% 60.58% 54.79% 54.90% 48.25% 51.36% 52.45% 55.21% 55.02% 57.32% 57.60% 58.62% 56.64% 58.84% 63.41% 63.71% 60.72% 62.12% 61.63% 61.64% 61.94%
Preferred stock 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01
Common stock 0.22 0.22 0.22 0.21 0.22 0.22 0.24 0.24 0.24 0.24 0.26 0.26 0.26 0.28 0.30 0.30 0.26 0.26 0.28 0.28 0.27 0.30 0.30
Additional paid-in capital 42.59 43.11 42.06 40.90 43.02 41.94 47.11 46.55 46.77 46.69 49.41 49.92 50.21 52.58 56.04 57.50 49.26 49.39 52.71 52.20 51.10 55.67 55.74
Treasury stock -52.29 -53.08 -51.90 -50.55 -53.24 -52.00 -58.52 -57.79 -58.33 -58.34 -61.97 -61.36 -62.15 -65.53 -70.11 -71.96 -62.01 -62.37 -66.74 -66.15 -65.00 -70.93 -71.28
Retained earnings 55.16 53.93 54.87 52.25 58.79 58.50 67.02 63.72 62.95 59.71 60.48 56.97 57.06 56.70 59.92 62.74 56.03 56.31 60.72 58.31 58.74 60.46 60.09
Accumulated other comprehensive loss -3.63 -3.62 -3.51 -3.51 -3.70 -3.68 -4.24 -4.21 -4.21 -3.65 -3.35 -3.25 -3.15 -2.80 -2.94 -7.58 -7.08 -7.44 -7.89 -6.95 -6.92 -7.38 -7.03
Total Pfizer Inc. shareholders’ equity 42.05% 40.57% 41.74% 39.30% 45.08% 44.97% 51.62% 48.51% 47.42% 44.66% 44.83% 42.54% 42.24% 41.22% 43.21% 41.00% 36.46% 36.16% 39.09% 37.70% 38.20% 38.14% 37.84%
Equity attributable to noncontrolling interests 0.12 0.13 0.12 0.12 0.13 0.12 0.14 0.13 0.13 0.13 0.14 0.14 0.15 0.16 0.15 0.15 0.13 0.13 0.19 0.18 0.17 0.23 0.23
Total equity 42.17% 40.69% 41.86% 39.42% 45.21% 45.10% 51.75% 48.64% 47.55% 44.79% 44.98% 42.68% 42.40% 41.38% 43.36% 41.16% 36.59% 36.29% 39.28% 37.88% 38.37% 38.36% 38.06%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Pfizer Inc. current liabilities as a percentage of total liabilities and equity increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Pfizer Inc. noncurrent liabilities as a percentage of total liabilities and equity decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Pfizer Inc. total liabilities as a percentage of total liabilities and equity increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Total Pfizer Inc. shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Pfizer Inc. total Pfizer Inc. shareholders’ equity as a percentage of total liabilities and equity decreased from Q1 2024 to Q2 2024 but then increased from Q2 2024 to Q3 2024 exceeding Q1 2024 level.